

GCIG Meta-Analysis
A pilot study

Surrogacy assessment of response to treatment in **first line ovarian cancers**

Xavier and Ros

Agenda

- Data Collection Status
- Setting up the Steering Commitee
- Launching a call for secondary questions
- Next steps

Objectives

In randomized trials of **adjuvant first line treatment ovarian cancer**

- Primary objective: to assess surrogate endpoints for OS of
  - Progression free survival defined as per GCIG criteria and by RECIST alone
  - Overall response using RECIST v1.1 measured at some time point (to be defined)

Objectives

- Secondary objectives:

1. to assess surrogate endpoints for PFS of
   - CA-125 dynamic over time
2. To assess surrogate value of $RMST_{PFS}$ for $RMST_{OS}$

- To evaluate the sensitivity of such PFS/OS (or CA-125/PFS) relationships according to
  - Maintenance, induction
  - Prognostic factors (age, cytoreductive status…)
  - Year of the clinical trial

Targeted trials (N=37, >28,000 patients …)

Trials published after 2001

3 groups of trials evaluating

1. the added value of **systemic trt** (no maintenance) to a standard of care (16 trials, N=14,571)
2. intensification regimen of various schedules (no maintenance) (5 trials, N=2,854)
3. maintenance treatments (16 trials, N=11,048) include 7 trials with MTA

Data Collection Status

(N=5 trials received, 9 (+1) with formal approval, 4 in process, 12 no news, 7 refusal)

Group	Nb of Trials	Comment
EORTC	1/1	
HeCOG	1/1	
GINECO	1/1	
MITO	2/3	MITO-1 to be provided

Data from 3,092 patients

Data Collection Status

(N=5 trials received, 9 (+1) with formal approval, 4 in process, 12 no news, 7 refusal)

Group	Nb of Trials	Comment
JGOG	2	New regulation in Japan for secondary use of data
SGCTG	2	Data extraction in process
CCTG (ex NCIC)	2	Data sharing agreement
Fruscio-2008	1	Data extraction in process
After-6 Protocol 1	1	Data extraction in process

+ MITO-01, in process
+ TriNOVA (BeGOG) when published

Expected data for 5,088 patients

Data Collection Status

(N=5 trials received, 9 (+1) with formal approval, 4 in process, 12 no news, 7 refusal)

Group	Nb of Trials	Comment
MRC	1/1	In review
GOG	3/3	In review

Data Collection Status

(N=5 trials received, 9 (+1) with formal approval, 4 in process, 12 no news, 7 refusal)

Group	Nb of Trials	Comment
NSGO (epirubicin)	1	Waiting for the executive committee decision on 05/05
Mouratidou-07 (cyclophosph.)	1	PI retired, data location unknown
vanderBurg-14 (intensification)	1	No feed back
Bolis-10 (topotecan)	1	No feed back
Goccne Group Nicoletto	1	No feed back
SWOG -9701 / GOG-178	1	No feed back
DoCaCel (celecoxib)	1	Stopped for excessive tox.
Pharma Company		
Eli Lilly	2	Who should be contacted?
Bayer (Sorafenib)	1	Who should be contacted?
Novartis	1	Who should be contacted?

Data Collection Status

(N=5 trials received, 9 (+1) with formal approval, 4 in process, 12 no news, 7 refusal)

Group	Nb of Trials	Comment
AGO	7/7	Authorship disagreement

➔ For intergroup trials, we will contact each contributing group to request access to National data

Secretariat

- Ros Glasspool (NHS Greater Glasgow and Clyde, UK) Xavier Paoletti and Eleni Karamuza (Gustave Roussy)
- Data sharing agreement with Gustave Roussy
- Data stored and back up at Gustave Roussy
- IRB approval

Steering Committee

- Who:
  - GCIG/EGOT group representatives interested in the project
    - Nelleke Ottevanger (EORTC)
    - Gerasimos Araventinos (HeCOG)
    - (GINECO)
    - (MITO)
  - Secretariat representatives (Ros and Xavier)
- What:
  - Review / hierarchize applications for scientific relevance and feasibility
  - Support and encourage data sharing
  - Apply terms of reference in case of disagreement

Secondary analyses

- Secondary projects can be proposed by contributing groups
  - Identify a PI, a stat.
  - Provide timelines
- **Each project must be approved**
  - For
    - Feasibility (do we have the data / variables / power)
    - Absence of overlapping (or merge the projects)
  - by
    - **the steering committee**
    - **in written by each sponsor for their data**
  - If not approved by certain sponsors, their particular data will not be included

- After approval by the SC, the secretariat will
  - request approval to each sponsor with the PI
  - request additional data if necessary
  - **make** the statistical analysis if funding is available
    or **run** the statistical analysis if no funding is available
    (the stat of the project, prepares the SAS program using a template of the database, and at Gustave Roussy we locally run the program)
- The PI will take the lead (first author)

Submitting a project for secondary analyses

At each GCIG meeting (or at intervening T/Cs), projects will be reviewed by the steering committee

- How:
  - Write a short outline (< 1p) with the statistician
    - setting, objective, endpoints, main stat method
    - targeted trials, requested variables
  - Source of funding

Secretariat will provide a list of collected variables and trials

Submitting a project for secondary analyses

Call for projects

- Open now
- To be evaluated in October, 2017
- 3 projects have been proposed
  - Prognostic value of lymphocytes and other markers of immunology at baseline (J Paul / SGCTG)
  - Predictive value of lymphocytes ratio (J-L Ethier / PMHC)
  - Prognostic value of CA125 summary (Kelim) in patients with paclitaxel intensification regimen (B You / GINECO)

We need more projects!

Next steps

- Data collection
  - Data checks, queries, validations of each trial with each sponsor
- Start meta-analysis of all trials collected end of 2017?
  - Surrogacy of PFS and OS

➔ What plan for communication?

- September: Review proposal for secondary analyses



GCIG Meta-Analysis
A pilot study

Surrogacy assessment of response to treatment in **first line ovarian cancers**

Xavier and Ros